human beta defensin-2 (hBD-2) / Defensin Therap - LARVOL DELTA

Host defense peptides human β defensin 2 and LL-37 ameliorate murine necrotizing enterocolitis. (PubMed, iScience) - "Both LL-37 and hBD2 resulted in decreased NEC injury scores as a treatment and hBD2 as a pretreatment. Our data suggest LL-37 functions through antimicrobial properties, while hBD2 functions through decreases in inflammation and improvement of intestinal barrier integrity."

Journal • Preclinical • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Septic Shock

Human α-Defensin 5 and Human β-Defensin 2 Improve Metabolic Parameters and Gut Barrier Function in Mice Fed a Western-Style Diet. (PubMed, Int J Mol Sci) - "While high-fructose and Western-style diet (WSD) disrupt intestinal barrier function, oral administration of human α-defensin 5 (HD5) and β-defensin 2 (hBD2) is believed to improve intestinal integrity and metabolic disorders...Moreover, peptide treatment restored ileal host defense peptides (HDP) expression, likely by modulating the Wnt, Myd88, p38, and Jak/STAT pathways. These findings strongly suggest that α- and β-defensin treatment improve hepatic steatosis, glucose metabolism, and gut barrier function."

Journal • Preclinical • Genetic Disorders • Hepatology • Metabolic Disorders • Non-alcoholic Fatty Liver Disease • Obesity • MYD88

Human β-defensin 2 ameliorates acute GVHD by limiting ileal neutrophil infiltration and restraining T cell receptor signaling. (PubMed, Sci Transl Med) - "Furthermore, hBD-2 treatment diminished alloreactive T cell infiltration and the expression of genes involved in T cell receptor signaling in the ilea of mice with aGVHD. Together, we found that both human and murine aGVHD were characterized by a lack of intestinal β-defensin induction and that recombinant hBD-2 represents a potential therapeutic strategy to counterbalance endogenous hBD-2 deficiency."

IO biomarker • Journal • Acute Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immune Modulation • Immunology • Inflammation • Leukemia • Oncology • CCR2 • CCR6

HUMAN ΒETA-DEFENSIN 2 TREATMENT MODULATES THE INTESTINAL MICROBIOME AND THE ALLOGENEIC T CELL RESPONSE TO LIMIT ACUTE GRAFT-VERSUS-HOST DISEASE (EHA 2022) - "Conclusion In conclusion, our study demonstrates that hBD-2 reduces acute GVHD severity, likely through its effects in shaping the intestinal microbiota, reducing neutrophil infiltration in the ileum and dampening allogeneic T cell responses. Both human and murine acute GVHD are characterized by a lack of intestinal beta-defensin induction and recombinant hBD-2 represents a potential novel therapeutic strategy to counterbalance endogenous hBD-2 deficiency."

IO biomarker • Acute Graft versus Host Disease • Gastroenterology • Gastrointestinal Disorder • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immune Modulation • Immunology • Inflammation • Inflammatory Bowel Disease • Leukemia • Oncology • Transplantation • Ulcerative Colitis • IFNG • MBD4

[VIRTUAL] HUMAN BETA DEFENSIN 2 ATTENUATED ALCOHOL-ASSOCIATED INTESTINE AND LIVER PATHOLOGY IN MICE: POTENTIAL ROLE FOR GUT MICROBIOME (DDW 2021) - "hBD-2 treatment attenuated EtOH-induced alterations in the liver and gut by targeting inflammation and injury. Our results suggest an important role for the gut microbiome in mediating the mechanisms of hBD-2 action. Future work will further explore the relationship between hBD-2, the gut microbiome, and ALD."

Preclinical • Addiction (Opioid and Alcohol) • Gastroenterology • Gastrointestinal Disorder • Hepatology • Immunology • Inflammation • Inflammatory Bowel Disease • Liver Failure • IL16 • IL22